Peptide API Manufacturers in China

Tianjin unit of Asymchem, a CDMO listed in Shenzhen and Hong Kong that makes peptides and oligos; US DMFs for liraglutide and semaglutide.

Model

CDMO

Manufacturer?

Yes

Changzhou API and tablet maker founded 1949 with a record of US FDA, EU GMP and PMDA inspections; US DMFs for semaglutide and tirzepatide.

Model

Manufacturer

Manufacturer?

Yes

Hangzhou peptide CRDMO founded in 2001, part of CPC Scientific/Medtide, with production in China and the USA. Holds US DMFs for cetrorelix, semaglutide and tirzepatide.

Model

CDMO

Manufacturer?

Yes

Neijiang, Sichuan injectables and API maker founded in 2010, listed on Shanghai's STAR Market, with FDA and UK MHRA GMP inspections; holds an active US DMF for lanreotide.

Model

CDMO

Manufacturer?

Yes

Jiangsu peptide CDMO and generic API supplier with large automated SPPS capacity; states it has passed four US FDA inspections. Holds US DMFs for 9 peptide APIs.

Model

CDMO

Manufacturer?

Yes

Chinese maker of generic small-molecule, peptide and oligonucleotide APIs, founded in 1998, with an FDA-inspected site in Yangzhou. Holds US DMFs for semaglutide and tirzepatide.

Model

Manufacturer

Manufacturer?

Yes

Chinese peptide drug manufacturer producing APIs and finished products.

Model

Manufacturer

Manufacturer?

Yes

Peptide and oligonucleotide CRDMO unit of WuXi AppTec, covering discovery through API and drug product manufacture. WuXi STA's peptide projects are routed to this platform.

Model

CDMO

Manufacturer?

Yes

Beijing API company, founded 2006, that holds DMFs and has its APIs made in partner facilities under its own quality control. Holds US DMFs for 13 peptide APIs.

Model

Manufacturer

Manufacturer?

Yes

Nanjing API subsidiary of Nasdaq-listed Amphastar; US DMF for teriparatide.

Model

Manufacturer

Manufacturer?

Yes

Chongqing maker of diabetes and obesity drugs, active since 2015 and controlled by Zhifei (300122) since 2025; US DMFs for liraglutide and semaglutide.

Model

Manufacturer

Manufacturer?

Yes

Chongqing API maker founded in 2016 covering high-potency APIs, peptides and XDC compounds with CDMO services; reports FDA on-site inspections in 2024 and 2025 and holds a US DMF for semaglutide.

Model

CDMO

Manufacturer?

Yes

Hangzhou recombinant drug maker listed in Hong Kong (02566), formerly Huadong Medicine's gene engineering centre; US DMF for liraglutide.

Model

Manufacturer

Manufacturer?

Yes

Hangzhou drug maker incorporated 1993, part of Shenzhen-listed Huadong Medicine; two group entities hold US DMFs for semaglutide.

Model

Manufacturer

Manufacturer?

Yes

Main operating subsidiary of Hong Kong-listed Hansoh Pharma, founded 1995; holds US DMFs for degarelix and icatibant.

Model

Manufacturer

Manufacturer?

Yes

Shenzhen peptide CDMO and API maker founded in 2009, with 13 cGMP lines and 85,000 L of SPPS/LPPS reactor volume. Holds US DMFs for 6 peptide APIs.

Model

CDMO

Manufacturer?

Yes

Shenzhen-listed drug maker (002294) selling APIs and finished products; US DMF for bivalirudin.

Model

Manufacturer

Manufacturer?

Yes

Suzhou API and intermediate maker founded in 2000 offering CDMO/CMO services; holds an active US DMF for semaglutide.

Model

CDMO

Manufacturer?

Yes

Suzhou peptide API and formulation maker founded in 2000, flagship of Tianma Pharma Group, offering CRO/CMO/CDMO services. Holds US DMFs for 8 peptide APIs.

Model

CDMO

Manufacturer?

Yes

Beijing biotech founded in 2018 that develops and produces recombinant protein and peptide drugs in E. coli for metabolic disease; holds an active US DMF for semaglutide.

Model

Manufacturer

Manufacturer?

Yes

Shanghai bulk peptide maker supplying wholesalers; holds US DMFs for bremelanotide, semaglutide and tirzepatide.

Model

Manufacturer

Manufacturer?

Yes

Putian, Fujian peptide API maker founded in 2019 by New Hope and Taiwan's Genovior, focused on GLP-1 APIs. Holds US DMFs for semaglutide and tirzepatide.

Model

Manufacturer

Manufacturer?

Yes

Zunyi, Guizhou peptide manufacturer offering development and kg-scale production; holds active US DMFs for tirzepatide and other peptides.

Model

CDMO

Manufacturer?

Yes

Hangzhou peptide and oligonucleotide CRDMO supporting projects from preclinical to commercial supply; holds active US DMFs for tirzepatide and inclisiran.

Model

CDMO

Manufacturer?

Yes

Hangzhou peptide maker founded in 2014 offering pharmaceutical, cosmetic and catalog peptides plus peptide CRO/CDMO work; holds an active US DMF for semaglutide.

Model

CDMO

Manufacturer?

Yes

Hangzhou peptide developer offering peptide APIs, intermediates, impurities and ADC/PDC linkers plus custom synthesis and process development; holds an active US DMF for tirzepatide.

Model

CDMO

Manufacturer?

Yes

Hangzhou peptide API maker and CDMO founded in 2019, supplying therapeutic and cosmetic peptides. Holds US DMFs for linaclotide, semaglutide and tirzepatide.

Model

CDMO

Manufacturer?

Yes

Changchun biopharmaceutical maker of somatropin, semaglutide and other APIs; holds active US DMFs for semaglutide and somatropin.

Model

Manufacturer

Manufacturer?

Yes

Nanjing supplier of insulin and metabolic peptide APIs with technology transfer services; US DMFs for semaglutide and tirzepatide.

Model

Manufacturer

Manufacturer?

Yes

Ningxia API and peptide maker founded in 2016 in Pingluo, offering peptide API development and manufacturing; holds US DMFs for semaglutide and tirzepatide.

Model

CDMO

Manufacturer?

Yes

Weihai Sino-US joint venture founded 2016 making peptide APIs and cosmetic peptides; US DMFs for leuprolide and semaglutide.

Model

Manufacturer

Manufacturer?

Yes

Shenzhen peptide company founded in 2020 making GLP-1 peptide APIs, sterile vials and peptide reference materials at a Zhongshan plant; holds an active US DMF for tirzepatide.

Model

Manufacturer

Manufacturer?

Yes

Shenzhen synthetic-biology ingredient maker with semaglutide as its lead biopharma product; US DMFs for semaglutide main chain and side chain.

Model

Manufacturer

Manufacturer?

Yes

Leshan-based peptide producer founded in 2015 with SPPS and LPPS lines; holds US DMFs for eptifibatide, semaglutide and tirzepatide.

Model

Manufacturer

Manufacturer?

Yes

Suzhou peptide CRDMO with GMP workshops built to ICH Q7; US DMFs for semaglutide and tirzepatide.

Model

CDMO

Manufacturer?

Yes

Suzhou API and intermediates producer offering customized manufacturing. Holds US DMFs for semaglutide, thymalfasin and tirzepatide.

Model

CDMO

Manufacturer?

Yes

Wuhan fermentation-based CDMO founded 2008 making GLP-1 APIs, proteases and cell products; US DMFs for semaglutide and its main chain.

Model

CDMO

Manufacturer?

Yes

Nantong company founded in 2020 that makes peptides by biosynthesis and offers peptide CMC development. Holds US DMFs for semaglutide and tirzepatide.

Model

CDMO

Manufacturer?

Yes

Hangzhou company founded in 2020 that makes GLP-1 peptides by fermentation plus semi-synthesis; holds an active US DMF for semaglutide API.

Model

Manufacturer

Manufacturer?

Yes

Harbin peptide API maker founded in 2011. Holds US DMFs for 11 peptide APIs. FDA issued it a CGMP warning letter in May 2026 that remains open.

Model

Manufacturer

Manufacturer?

Yes

Nanjing maker of peptide, protein and polysaccharide APIs and finished products, registered in 2017. Holds US DMFs for semaglutide and tirzepatide. FDA warning letter issued Nov 2026.

Model

Manufacturer

Manufacturer?

Yes

Large Zhejiang API and generic drug maker founded in 1989 and listed in Shanghai; holds active US DMFs for semaglutide and a semaglutide intermediate. It has an open FDA warning letter from June 2025.

Model

Manufacturer

Manufacturer?

Yes